Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
28 USD | +0,41 % | -1,42 % | -0,96 % |
Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Biopharmaceutical Royalties
100,0
%
| 2 237 | 100,0 % | 2 355 | 100,0 % | +5,24 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 2 237 | 100,0 % | 2 355 | 100,0 % | +5,24 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 01.01.96 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 01.01.10 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 21.09.23 |
James Reddoch
CTO | Chief Tech/Sci/R&D Officer | 54 | 01.07.08 |
Arthur McGivern
CIO | Chief Investment Officer | - | 12.10.22 |
Sara Klymkowsky
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.12 |
Brienne Kugler
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.14 |
George Lloyd
CIO | Chief Investment Officer | 64 | 01.01.11 |
Christopher Hite
BRD | Director/Board Member | 57 | 01.03.20 |
George Grofik
IRC | Investor Relations Contact | - | 01.01.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 01.01.96 |
Errol de Souza
BRD | Director/Board Member | 70 | 01.06.20 |
David Hodgson
BRD | Director/Board Member | 67 | 23.06.22 |
Ted Love
BRD | Director/Board Member | 65 | 30.07.20 |
Henry Fernandez
BRD | Director/Board Member | 65 | 30.07.20 |
Gregory Norden
BRD | Director/Board Member | 66 | 11.02.20 |
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 01.01.96 |
Mario Giuliani
BRD | Director/Board Member | 52 | 01.06.20 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 16.06.20 |
Christopher Hite
BRD | Director/Board Member | 57 | 01.03.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 50 000 | 0 | 0 | 95,08 % |
Aktie B | 1 | 150 743 276 | 0 | 0 | |
Aktie C | 1 | 446 691 515 | 424 704 211 ( 95,08 %) | 0 |
Unternehmenskontakt
Royalty Pharma Plc
110 East 59th Street 33rd floor
10022, New York
+212 883 0200
http://www.royaltypharma.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Royalty Pharma Holdings Ltd.
Royalty Pharma Holdings Ltd. Financial ConglomeratesFinance Royalty Pharma Holdings Ltd. operates as an investment holding company. The company was founded on February 10, 2020 and is headquartered in Bristol, the United Kingdom. |
Financial Conglomerates
|
Sektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-0,96 % | 12,46 Mrd. | |
+24,97 % | 672 Mrd. | |
+24,08 % | 550 Mrd. | |
-6,31 % | 351 Mrd. | |
+15,14 % | 317 Mrd. | |
+7,37 % | 292 Mrd. | |
+3,26 % | 211 Mrd. | |
+0,78 % | 203 Mrd. | |
-10,47 % | 144 Mrd. | |
-7,38 % | 141 Mrd. |
- Börse
- Aktien
- A2P62D Aktie
- Unternehmen Royalty Pharma plc